Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL

Leukemia

Volumn 23, Issue 12, 2009, Pages 2242-2247

  Mian, A A ^a   Oancea, C ^a   Zhao, Z ^a   Ottmann, O G ^a   Ruthardt, M ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

allosteric inhibition; BCR ABL; gatekeeper mutation T315I; imatinib resistance; inhibition of oligomerization; Philadelphia chromosome positive leukemia

Indexed keywords

BCR ABL PROTEIN; GNF 2 COMPOUND; GNF-2 COMPOUND; PYRIMIDINE DERIVATIVE;

ALLOSTERISM; ANIMAL; ARTICLE; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION; CHEMISTRY; DRUG EFFECT; GENETICS; METABOLISM; MISSENSE MUTATION; MOUSE; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; RAT;

ALLOSTERIC REGULATION; ANIMALS; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FUSION PROTEINS, BCR-ABL; MICE; MUTATION, MISSENSE; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; PYRIMIDINES; RATS;

EID: 74049164212     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.194     Document Type: Article

References (18)

1. Ottmann OG, Wassmann B. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2005, 118-122.
2. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164-172. (Pubitemid 29325745)
3. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247: 1079-1082.
4. Deininger M. Resistance to imatinib: mechanisms and management. J Natl Compr Canc Netw 2005; 3: 757-768. (Pubitemid 44265404)
5. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008; 112: 4808-4817.
6. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000; 5: 3498-3505. (Pubitemid 30428483)
7. Ramirez P, DiPersio JF. Therapy options in imatinib failures. Oncologist 2008; 13: 424-434. (Pubitemid 351679922)
8. Cowan-Jacob SW, Guez V, Fendrich G, Griffin JD, Fabbro D, Furet P et al. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev Med Chem 2004; 4: 285-299. (Pubitemid 38854871)
9. Beissert T, Puccetti E, Bianchini A, Guller S, Boehrer S, Hoelzer D et al. Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571. Blood 2003; 102: 2985-2993. (Pubitemid 37248874)
10. Zhao X, Ghaffari S, Lodish H, Malashkevich VN, Kim PS. Structure of the Bcr-Abl oncoprotein oligomerization domain. Nat Struct Biol 2002; 9: 117-120. (Pubitemid 34132413)
11. Smith KM, Yacobi R, Van Etten RA. Autoinhibition of Bcr-Abl through its SH3 domain. Mol Cell 2003; 12: 27-37. (Pubitemid 36945035)
12. Beissert T, Hundertmark A, Kaburova V, Travaglini L, Mian AA, Nervi C et al. Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL. Int J Cancer 2008; 122: 2744-2752. (Pubitemid 351631376)
13. Hantschel O, Nagar B, Guettler S, Kretzschmar J, Dorey K, Kuriyan J et al. A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 2003; 112: 845-857. (Pubitemid 36378886)
14. Hantschel O, Superti-Furga G. Regulation of the c-Abl and BCR/ABL tyrosine kinases. Nat Rev Mol Cell Biol 2004; 5: 33-44. (Pubitemid 38089839)
15. Franz WM, Berger P, Wang JY. Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential. EMBO J 1989; 8: 137-147. (Pubitemid 19273956)
16. Adrián FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol Biol Chem 2006; 2: 95-102.
17. Mian AA, Schü ll M, Zhao Z, Oancea C, Hundertmark A, Beissert T et al. The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABL. Leukemia 2009; 23: 1614-1621.
18. Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol 2008; 15: 1109-1118.